INTRODUCTION AND OBJECTIVES: Mortality due to AKI has not changed significantly over the past 50 years.
This is due in part to failure to detect early AKI and to initiate appropriate therapeutic measures. There is therefore a need to identify biomarkers that would improve the early detection of AKI. The objective of this study was to assess whether cystatin C levels obtained at specific timepoints during laparoscopic partial nephrectomy (PN) could be early predictors of AKI.
MATERIALS AND METHODS: Twenty-five patients underwent laparoscopic PN for organ-confined tumors. All procedures were performed by two surgeons in a single institution. Plasma samples were collected preoperatively, and post-unclamping at 5, 20, 120 min and on the day following surgery. Plasma cystatin C was measured by enzyme-linked immunosorbent assay. Correlation between levels of cystatin C and other parameters of interest were assessed in order to define cystatin C ability to predict AKI and loss of renal function following laparoscopic PN.
RESULTS: The mean baseline eGFR was 93 ml/min/1.73 m2. Warm ischemia time varied between 16 and 44 min. Post-operative day 1 (POD1) cystatin C levels compared to baseline were increased in 13 (52%) of the patients. There was a high correlation between the difference of POD 1 and baseline value, and eGFR in the immediate postoperative period (r = -0.681; P = 0.0002) and at 12-month follow-up (r = -0.460, P = 0.048). However, the variation in cystatin C levels at earlier timepoints were not associated to AKI nor renal function.
CONCLUSIONS: High increase in POD 1 cystatin C levels from baseline may help identify patients with AKI and those at higher risk of chronic kidney disease, following laparoscopic PN.
Written by:
Alesawi A, Nadeau G, Bergeron A, Dujardin T, Lacombe L, Caumartin Y. Are you the author?
Department of Urology of Laval University, CHU de Québec - L'Hôtel-Dieu de Québec, Québec, Qc, Canada; Laval University Cancer Research Centre, CHU de Québec - L'Hôtel-Dieu de Québec, Québec, Qc, Canada; Laval University Cancer Research Centre, CHU de Québec - L'Hôtel-Dieu de Québec, Québec, Qc, Canada.
Reference: Urol Ann. 2014 Oct;6(4):298-304.
doi: 10.4103/0974-7796.140988
PubMed Abstract
PMID: 25371605